Comparative efficacy between venlafaxine and SSRIs: A pooled analysis of patients with depression

Biological Psychiatry

Volumn 52, Issue 12, 2002, Pages 1166-1174

  Stahl, Stephen M ^a,b   Entsuah, Richard ^a,b   Rudolph, Richard L ^a,b  

^a NEUROSCIENCE EDUCATION INSTITUTE   (United States)

^b PFIZER INC   (United States)

Author keywords

Depression; Efficacy; Norepinephrine; Selective serotonin reuptake inhibitors; Serotonin; Venlafaxine

Indexed keywords

FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HAMILTON SCALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NERVOUSNESS; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; SWEATING; TREATMENT OUTCOME; TREMOR; VERTIGO; XEROSTOMIA;

ADULT; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CLINICAL TRIALS; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; FLUVOXAMINE; HUMANS; MALE; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 0037115290     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(02)01425-7     Document Type: Article

References (38)

1. Alves C., Cachola I., Brandao J. Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression. Primary Care Psychiatry. 5:1999;57-63.
2. Diagnostic and Statistical Manual of Mental Disorders DSM-III-R . 3rd ed:1987;American Psychiatric Association, Washington, DC.
3. Diagnostic and Statistical Manual of Mental Disorders DSM-IV . 4th ed:1994;American Psychiatric Association, Washington, DC.
4. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry. 157:(suppl):2000;1-45.
5. Anderson I.M. SSRIs versus tricyclic antidepressants in depressed inpatients A meta-analysis of efficacy and tolerability . Depress Anxiety. 7:(suppl 1):1998;11-17.
6. Anderson I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants A meta-analysis of efficacy and tolerability . J Affect Disord. 58:2000;19-36.
7. Anderson I.M., Tomenson B.M. The efficacy of selective serotonin re-uptake inhibitors in depression A meta-analysis of studies against tricyclic antidepressants . J Psychopharmacol. 8:1994;238-249.
8. Ballús C., Quiros G., de Flores T., de la Torre J., Palao D., Rojo L., et al. The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. Int Clin Psychopharmacol. 15:2000;43-48.
9. Clerc G.E., Ruimy P., Verdeau-Paillès J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol. 9:1994;139-143.
10. Costa e Silva J. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry. 59:1998;352-357.
11. Citalopram: Clinical effect profile in comparison with clomipramine A controlled multicenter study . Psychopharmacology. 90:1986;131-138.
12. Paroxetine A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study . J Affect Disord. 18:1990;289-299.
13. Clinical Practice Guideline Number 5 Depression in Primary Care, Vol. 1 . Detection and Diagnosis AHCPR Publication 93-0550. 1990;U.S. Dept of Health and Human Services, Agency for Health Care Policy and Research, Rockville, MD.
14. Diaz-Martinez A., Benassinni O., Ontiveros A., Gonzalez S., Salin R., Basquedano G., et al. A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients. Clin Ther. 20:1998;467-476.
15. Dierick M., Ravizza L., Realini R., Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry. 20:1996;57-71.
16. Freemantle N., Anderson I.M., Young P. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs Meta-regression analysis . Br J Psychiatry. 177:2000;292-302.
17. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 23:1960;56-62.
18. Harvey A.T., Rudolph R.L., Preskorn S.H. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry. 57:2000;503-509.
19. Leinonen E., Skarstein J., Behnke K., Agren H., Helsdingen J.T. Efficacy and tolerability of mirtazapine versus citalopram A double-blind, randomized study in patients with major depressive disorder . Int Clin Psychopharmacol. 14:1999;329-337.
20. Lopez-Ibor J., Guelfi J.D., Pletan Y., Tournoux A., Prost J.F. Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol. 11:(suppl 4):1996;41-46.
21. McPartlin G.M., Reynolds A., Anderson C., Casoy J. A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice. Primary Care Psychiatry. 4:1998;127-132.
22. Mehtonen O.-P., Søgaard J., Roponen P., Behnke K. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. J Clin Psychiatry. 61:2000;95-100.
23. Montgomery S.A., Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 134:1979;382-389.
24. Clinical Global Impressions. Psychopharmacol Bull. 21:1985;839-843.
25. Nelson J.C. A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression. Biol Psychiatry. 46:1999;1301-1308.
26. Nelson J.C., Mazure C.M., Bowers M.B. Jr, Jatlow P.I. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry. 48:1991;303-307.
27. Poirier M.-F., Boyer P. Venlafaxine and paroxetine in treatment-resistant depression Double-blind, randomised comparison . Br J Psychiatry. 175:1999;12-16.
28. Prien R.F. Clinical Evaluation of Psychotropic Drugs Principles and Guidelines . 1994;Lippincott Williams and Wilkins, New York.
29. Roose S.P., Glassman A.H., Attia E., Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry. 151:1994;1735-1739.
30. Rudolph R, Entsuah R, Aguiar L, Derivan A (1998, November): Early onset of antidepressant activity of venlafaxine compared with placebo and fluoxetine in outpatients in a double-blind study. Poster presented at the Annual Meeting of the European College of Neuropsychopharmacology, Paris, France.
31. Rudolph R.L., Feiger A.D. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord. 56:1999;171-181.
32. Salinas E, for the Venlafaxine 367 Study Group (1998, November): Once-daily venlafaxine XR versus paroxetine in outpatients with major depression. Poster presented at the Annual Meeting of the European College of Neuropsychopharmacology, Paris, France.
33. Silverstone P.H., Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatry. 60:1999;22-28.
34. Stahl S.M. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol Psychiatry. 48:2000;894-901.
35. Steffens D.C., Krishnan K.R.R., Helms M.J. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs A meta-analysis . Depress Anxiety. 6:1997;10-18.
36. Thase M.E., Entsuah A.R., Rudolph R.L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 178:2001;234-241.
37. Tylee A., Beaumont G., Bowden M.W., Reynolds A. A double-blind, randomized, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice. Primary Care Psychiatry. 3:1997;51-58.
38. Tzanakaki M., Guazzelli M., Nimatoudis I., Zissis N.P., Smeraldi E., Rizzo F. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia. [erratum published Int Clin Psychopharmacol 2001;15:120] Int Clin Psychopharmacol. 15:2000;29-34.